<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00452699</url>
  </required_header>
  <id_info>
    <org_study_id>ADA109055</org_study_id>
    <nct_id>NCT00452699</nct_id>
  </id_info>
  <brief_title>A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma</brief_title>
  <official_title>A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Treatment of Subjects With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This purpose of this study is to show the superiority and long term safety and efficacy of
      adding a long acting beta agonist (salmeterol) to constant dose of an inhaled corticosteroid
      (fluticasone propionate) in symptomatic subjects with asthma. The 12-month assessment of
      asthma control will provide key information on the efficacy and safety of the combination
      therapy. The safety measure will be an assessment of adverse events
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in Pre-dose FEV1 Over Weeks 1-52</measure>
    <time_frame>Baseline and Week 1 through Week 52</time_frame>
    <description>Pulmonary function was measured by forced expiratory volume in one second (FEV1), which is the volume of air exhaled from the lungs in one second. Change from baseline was calculated as the average of the Week 1 through Week 52 values minus the baseline value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in AM PEF Over Weeks 1-52</measure>
    <time_frame>Baseline and Week 1 through Week 52</time_frame>
    <description>Morning (AM) peak expiratory flow (PEF) is defined as the maximum volume of air exhaled in liters per minute. Change from baseline was calculated as the average of the Week 1 through Week 52 values minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Percentage of Symptom-free Days Over Weeks 1-52</measure>
    <time_frame>Baseline and Week 1 through Week 52</time_frame>
    <description>A symptom-free day was defined as a day without asthma symptoms, as measured via the daily asthma symptom score (measuring symptoms during the day and previous night) on a 6-point scale (ranging from 0 to 5). A symptom score of 0=no symptoms, 1=symptoms for one short period, 2=symptoms for two or more short periods, 3=symptoms that did not affect normal daily activities, 4=symptoms that did affect normal daily activities, 5=symptoms so severe that daily activities could not be performed. Change from baseline was calculated as the average of the Week 1-Week 52 values minus the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Asthma Attacks Per Participant Per Year</measure>
    <time_frame>Week 1 through Week 52</time_frame>
    <description>The rate of asthma attacks was defined as the mean number of attacks per participant per year. An asthma attack was defined as a 20% decrease in AM PEF, a 70% increase in albuterol use, or the occurrence of an asthma exacerbation requiring oral steroids or hospitalization.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">621</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluticasone propionate 250 mcg BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluticasone propionate 250 mcg BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID</intervention_name>
    <description>Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID</description>
    <arm_group_label>Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone propionate 250 mcg BID</intervention_name>
    <description>Fluticasone propionate 250 mcg BID</description>
    <arm_group_label>Fluticasone propionate 250 mcg BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects eligible for enrollment in the study must meet all of the following criteria:

          -  Consent: A signed and dated written informed consent must be obtained from the subject
             and/or subject's legally acceptable representative prior to study participation.

          -  Type of Subject: Outpatient

          -  Gender: Male or female Females are eligible to participate only if they are currently
             non-pregnant and non-lactating.

        A female is eligible to enter and participate in the study if she is:

          1. of non-child-bearing potential; OR

          2. of child-bearing potential but has a negative urinary pregnancy test at Screening
             (Visit 1 and when specified in Appendix 1) and agrees to take contraceptive
             precautions (including abstinence) which are adequate to prevent pregnancy during the
             study.

             Acceptable methods of contraception [Hatcher, 2004] are:

             - Abstinence

               -  oral contraceptive (either combined or progestogen only)

               -  injectable progestogen

               -  implants of levonorgestrel

               -  estrogenic vaginal ring

               -  percutaneous contraceptive devices

               -  intrauterine device (IUD) or intrauterine system (IUS) with published data
                  showing that the lowest expected failure rate is less than 1% per year

               -  male partner sterilization (vasectomy with documentation of azoospermia) prior to
                  the female subject's entry into the study and is the sole sexual partner for that
                  female subject

               -  double barrier method: condom or occlusive cap (diaphragm or cervical/vault caps)
                  plus spermicidal agent

                    1. Age: A subject must be 12 years of age at Visit 1 (screening).

                    2. Asthma Diagnosis: A documented diagnosis of persistent asthma, for at least
                       six months, as defined by the following American Thoracic Society
                       definition:

             Asthma is a clinical syndrome characterized by increased responsiveness of the airways
             to a variety of stimuli. The major symptoms of asthma are episodes of dyspnea,
             wheezing, and cough, which may vary from mild and almost undetectable to severe and
             unremitting (status asthmaticus). The primary physiological manifestation of this
             hyperresponsiveness is variable airway obstruction. This can take the form of
             spontaneous fluctuations in the severity of obstruction, substantial improvements in
             the severity of obstruction following bronchodilators or corticosteroids, or increased
             obstruction caused by drugs or other stimuli [American Thoracic Society, 1987].

               1. Asthma Medication History: A subject must be using a low to medium dose of an ICS
                  (Table 1) OR a combination of controller medications (Table 2), containing a low
                  (total daily) dose ICS (as defined in Table 1) for at least 4 weeks preceding
                  screening.

             Table 1 (ICS Dosage Table) Inhaled Corticosteroid (Dosage (mcg/day))(LowMedium)
             Beclomethasone dipropionate CFC(168 = 504&gt; 504 = 840) Beclomethasone dipropionate HFA
             (80 = 240&gt;240 = 640) Triamcinolone acetonide(400 = 1000&gt;1000 = 2000) Flunisolide (500
             = 1000&gt; 1000 = 2000) Fluticasone propionate inhalation aerosol (176 = 220&gt; 220 = 440)
             Fluticasone propionate inhalation powder (100 = 250&gt; 250 = 500) Budesonide1 (200 =
             600&gt; 600 =1200) Mometasone (200 = 400&gt; 400 = 800) Ciclesonide (80 = 160&gt;160 = 320)

             1.Respules are allowed at a dosage of 250-500mcg/day.

             Table 2 (Asthma Controller Medications) Asthma Controller Medication(s) Low dose ICS +
             Leukotriene modifiers Low dose ICS + Theophylline products Low Dose ICS + Inhaled
             anticholinergics or combination products (e.g., Atrovent or Combivent) Low Dose ICS +
             Long acting inhaled anticholinergic (e.g. Spiriva) Low dose ICS+ long acting beta
             agonist or combination products containing a low dose ICS and a long-acting
             beta-agonists (e.g. ADVAIR™/SERETIDE™1 100/50 mcg BID or Symbicort 160/9 mcg BID (i.e
             80/4.5 mcg two inhalations BID)

             1) ADVAIR/SERETIDE =250/50 mcg BID or Symbicort 320/9 mcg BID (i.e 160/4.5 mcg two
             inhalation BID) are not permitted.

               1. Pulmonary function: A pre-albuterol (salbutamol) FEV1 of 50% and 85% of predicted
                  normal value at screening (Visit 1) after withholding asthma medications as
                  detailed in the protocol (Section 6.8.1). Predicted FEV1 will be based on the
                  National Health and Nutrition Examination Survey (NHANES III) predicted normal
                  values for ages 8 years and older [Hankinson, 1999].

               2. Reversibility: An increase in FEV1 of 12% over the pre-albuterol (salbutamol)
                  FEV1 within 30 minutes after the inhalation of 2-4 puffs of albuterol
                  (salbutamol). Historical documentation of reversibility will not be permitted.

               3. Asthma symptom criteria: Each subject must have experienced asthma symptoms
                  requiring albuterol (salbutamol) use within the 4 weeks preceding screening
                  (Visit 1).

             Specific information regarding warnings, precautions, contraindications, adverse
             events, and other pertinent information on the investigational product that may impact
             subject eligibility is provided in the IB and the product labels.

             Exclusion Criteria:

             - Subjects meeting any of the following criteria must not be enrolled in the study:

               1. Life-Threatening Asthma: A subject must not have life-threatening asthma.
                  Life-threatening asthma is defined for this protocol as a history of significant
                  asthma episode(s) requiring intubation associated with hypercapnia, respiratory
                  arrest, or hypoxic seizures, or asthma-related syncopal episode(s) within the 12
                  months prior to screening (Visit 1).

               2. Worsening of Asthma: A subject must not have experienced a worsening of asthma
                  which involved an ER visit, hospitalization or use of oral/parenteral
                  corticosteroids within 4 weeks of screening (Visit 1).

               3. Intermittent, Seasonal, or Exercise-Induced Asthma Alone: Subjects with only
                  intermittent or seasonal or exercise-induced asthma are excluded from
                  participation in this study.

               4. Concurrent Respiratory Disease: A subject must not have current evidence of
                  pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, chronic
                  bronchitis, emphysema, chronic obstructive pulmonary disease, or other
                  respiratory abnormalities other than asthma.

               5. Concurrent Conditions/Diseases: A subject with historical or current evidence of
                  any clinically significant, co-morbid or uncontrolled condition or disease state
                  that, in the opinion of the investigator, would put the safety of the subject at
                  risk through study participation or would confound the interpretation of the
                  results if the condition/disease exacerbated during the study.

             The list of excluded conditions/diseases includes, but is not limited to:

             congestive heart failure known aortic aneurysm clinically significant coronary
             clinically significant cardiac arrhythmia heart disease stroke within 3 months of
             screening (Visit 1) uncontrolled hypertension coronary artery disease hematologic,
             hepatic, or renal disease cystic fibrosis poorly controlled peptic ulcer dyspnea by
             any other cause than asthma gastroesophageal reflux disease (GERD) not controlled by
             pharmacotherapy and may be causing/contributing to subject's respiratory symptoms
             thyrotoxicosis hypokalemia immunologic compromise current malignancy1 tuberculosis
             (current or quiescent) Cushing's or Addison's disease pneumonia, pneumothorax, chronic
             bronchitis or atelectasis uncontrolled diabetes mellitus recent history of drug or
             alcohol abuse 1) history of malignancy is acceptable only if subject has been in
             remission for one year prior to screening (Visit 1; remission = no treatment for the
             malignancy in the 12 months prior to screening [Visit 1])

               -  Drug Allergy: A subject must not have had any immediate or delayed
                  hypersensitivity to any beta2-agonist; sympathomimetic drug; any intranasal;
                  inhaled or systemic corticosteroid therapy; lactose; or have a severe milk
                  protein allergy.

               -  Respiratory Tract Infections: A subject must not have had any sinus, middle ear,
                  oropharyngeal, upper or lower respiratory tract infection symptoms that have not
                  resolved at least 7 days immediately preceding screening (Visit 1).

                  3. Asthma Medications: Asthma medications listed below must not have been used
                  prior to screening (Visit 1) for the required exclusion period as indicated
                  below:

             Medication (Exclusion Period Prior to screening (Visit 1)) Oral or parenteral systemic
             corticosteroids (4 weeks) Omalizumab (Xolair) (6 months)

               1. Concurrent Medications: A subject must not have the concurrent use of any of the
                  following medications that interact with any of the study drugs used in this
                  study, or that may affect the course of asthma or interact with sympathomimetic
                  amines, such as:

                  - beta-adrenergic receptor blocking agents

                  - monoamine oxidase (MAO) inhibitors

                  - tricyclic antidepressants

                  - ritonavir

                    -  ketoconazole

               2. Concurrent use of asthma medications: Concurrent use of all asthma medications
                  (other than protocol defined study and rescue medications and oral/parenteral
                  corticosteroids) are prohibited during the study.

               3. Concomitant use of leukotriene modifiers (LTM) for allergies is prohibited. A
                  subject must not be on LTM for treatment of nasal allergies that requires regular
                  maintenance therapy. Substitution with any other antihistamine is permitted.

               4. Immunosuppressive Medications: A subject must not be using, or require the use
                  of, immunosuppressive medications during the study.

               5. Immunotherapy for the treatment of allergies is not allowed during the study
                  unless the subject has used a constant dose for 4 weeks prior to Screening (Visit
                  1) and the same dose will be continued throughout the study.

               6. Tobacco Use: &gt;10 pack year history or use of any tobacco products within 1 year
                  of screening (Visit 1). This includes cigarettes, cigars, pipe, chewing tobacco,
                  and snuff.

               7. Questionable Validity of Consent: A subject must not have any infirmity or
                  disability that would limit the subject's consent.

               8. Positive Pregnancy Test (for all females who have had menarche): A current
                  positive pregnancy test.

               9. Investigational Medications: A subject must not have had use of any
                  investigational drug within 30 days of screening (Visit 1).

              10. Site Affiliation: A subject may not participate if he/she is a participating
                  investigator, sub-investigator, study coordinator, employee of a participating
                  investigator or is in any way associated with the administration of the study.
                  Immediate family members of these individuals are also excluded.

              11. Compliance with Study Requirements: A subject may not participate if, in the
                  opinion of the investigator, there are present or anticipated circumstances that
                  will prohibit the subject from being compliant with study visits and procedures
                  (e.g. geographic location that will prohibit subject from required clinic visit
                  schedule).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1690</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Conyers</city>
        <state>Georgia</state>
        <zip>30013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lilburn</city>
        <state>Georgia</state>
        <zip>30047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bozeman</city>
        <state>Montana</state>
        <zip>59718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Utica</city>
        <state>New York</state>
        <zip>13502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tigard</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <zip>02914</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gaffney</city>
        <state>South Carolina</state>
        <zip>29340</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Union</city>
        <state>South Carolina</state>
        <zip>29309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78750</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Corsicana</city>
        <state>Texas</state>
        <zip>75110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79925</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Olympia</city>
        <state>Washington</state>
        <zip>98506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Allis</city>
        <state>Wisconsin</state>
        <zip>53227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1122AAK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Plata</city>
        <state>Buenos Aires</state>
        <zip>1900</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nueve de Julio</city>
        <state>Buenos Aires</state>
        <zip>B6500BWQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vicente López</city>
        <state>Buenos Aires</state>
        <zip>1602</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1424BSF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salvador</city>
        <state>Bahía</state>
        <zip>41940455</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30130-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Recife</city>
        <state>Pernambuco</state>
        <zip>50670-420</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L4W 1N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charlottetown</city>
        <state>Prince Edward Island</state>
        <zip>C1A 5Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7K 7H9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cavite</city>
        <zip>4114</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lipa City</city>
        <zip>4217</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1101</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Philippines</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Anderson WH, Koshy BT, Huang L, Mosteller M, Stinnett SW, Condreay LD, Ortega H. Genetic analysis of asthma exacerbations. Ann Allergy Asthma Immunol. 2013 Jun;110(6):416-422.e2. doi: 10.1016/j.anai.2013.04.002.</citation>
    <PMID>23706709</PMID>
  </reference>
  <reference>
    <citation>Katial RK, Bernstein D, Prazma CM, Lincourt WR, Stempel DA. Long-term treatment with fluticasone propionate/salmeterol via Diskus improves asthma control versus fluticasone propionate alone. Allergy Asthma Proc. 2011 Mar-Apr;32(2):127-36. doi: 10.2500/aap.2011.32.3426. Epub 2010 Dec 28.</citation>
    <PMID>21189151</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2007</study_first_submitted>
  <study_first_submitted_qc>March 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2007</study_first_posted>
  <results_first_submitted>January 14, 2010</results_first_submitted>
  <results_first_submitted_qc>January 25, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 15, 2010</results_first_posted>
  <last_update_submitted>October 26, 2016</last_update_submitted>
  <last_update_submitted_qc>October 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fluticasone propionate</keyword>
  <keyword>long-term study</keyword>
  <keyword>Salmeterol</keyword>
  <keyword>FLOVENT 250</keyword>
  <keyword>Asthma</keyword>
  <keyword>ADVAIR 250</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>ADA109055</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>ADA109055</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>ADA109055</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>ADA109055</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>ADA109055</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>ADA109055</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>ADA109055</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>FSC DISKUS 250/50 mcg BID for 52 Weeks</title>
          <description>Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 micrograms (mcg) twice daily (BID) for 52 weeks</description>
        </group>
        <group group_id="P2">
          <title>FP DISKUS 250 mcg BID for 52 Weeks</title>
          <description>Fluticasone Propionate (FP) DISKUS 250 mcg BID for 52 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="306"/>
                <participants group_id="P2" count="315"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="225"/>
                <participants group_id="P2" count="242"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="73"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FSC DISKUS 250/50 mcg BID for 52 Weeks</title>
          <description>Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 micrograms (mcg) twice daily (BID) for 52 weeks</description>
        </group>
        <group group_id="B2">
          <title>FP DISKUS 250 mcg BID for 52 Weeks</title>
          <description>Fluticasone Propionate (FP) DISKUS 250 mcg BID for 52 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="306"/>
            <count group_id="B2" value="315"/>
            <count group_id="B3" value="621"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.8" spread="15.52"/>
                    <measurement group_id="B2" value="39.3" spread="15.52"/>
                    <measurement group_id="B3" value="38.1" spread="15.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="191"/>
                    <measurement group_id="B2" value="201"/>
                    <measurement group_id="B3" value="392"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="197"/>
                    <measurement group_id="B2" value="208"/>
                    <measurement group_id="B3" value="405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Pre-dose FEV1 Over Weeks 1-52</title>
        <description>Pulmonary function was measured by forced expiratory volume in one second (FEV1), which is the volume of air exhaled from the lungs in one second. Change from baseline was calculated as the average of the Week 1 through Week 52 values minus the baseline value.</description>
        <time_frame>Baseline and Week 1 through Week 52</time_frame>
        <population>Intent-to-Treat (ITT) Population: all participants randomized to study drug</population>
        <group_list>
          <group group_id="O1">
            <title>FSC DISKUS 250/50 mcg BID for 52 Weeks</title>
            <description>Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 micrograms (mcg) twice daily (BID) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>FP DISKUS 250 mcg BID for 52 Weeks</title>
            <description>Fluticasone Propionate (FP) DISKUS 250 mcg BID for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Pre-dose FEV1 Over Weeks 1-52</title>
          <description>Pulmonary function was measured by forced expiratory volume in one second (FEV1), which is the volume of air exhaled from the lungs in one second. Change from baseline was calculated as the average of the Week 1 through Week 52 values minus the baseline value.</description>
          <population>Intent-to-Treat (ITT) Population: all participants randomized to study drug</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="306"/>
                <count group_id="O2" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.017"/>
                    <measurement group_id="O2" value="0.09" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.07</ci_lower_limit>
            <ci_upper_limit>0.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in AM PEF Over Weeks 1-52</title>
        <description>Morning (AM) peak expiratory flow (PEF) is defined as the maximum volume of air exhaled in liters per minute. Change from baseline was calculated as the average of the Week 1 through Week 52 values minus the baseline value.</description>
        <time_frame>Baseline and Week 1 through Week 52</time_frame>
        <population>Participants in the ITT Population who had a minimum of 1 week PEF values</population>
        <group_list>
          <group group_id="O1">
            <title>FSC DISKUS 250/50 mcg BID for 52 Weeks</title>
            <description>Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 micrograms (mcg) twice daily (BID) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>FP DISKUS 250 mcg BID for 52 Weeks</title>
            <description>Fluticasone Propionate (FP) DISKUS 250 mcg BID for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in AM PEF Over Weeks 1-52</title>
          <description>Morning (AM) peak expiratory flow (PEF) is defined as the maximum volume of air exhaled in liters per minute. Change from baseline was calculated as the average of the Week 1 through Week 52 values minus the baseline value.</description>
          <population>Participants in the ITT Population who had a minimum of 1 week PEF values</population>
          <units>Liters/minute (L/min)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.6" spread="2.47"/>
                    <measurement group_id="O2" value="9.8" spread="2.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Percentage of Symptom-free Days Over Weeks 1-52</title>
        <description>A symptom-free day was defined as a day without asthma symptoms, as measured via the daily asthma symptom score (measuring symptoms during the day and previous night) on a 6-point scale (ranging from 0 to 5). A symptom score of 0=no symptoms, 1=symptoms for one short period, 2=symptoms for two or more short periods, 3=symptoms that did not affect normal daily activities, 4=symptoms that did affect normal daily activities, 5=symptoms so severe that daily activities could not be performed. Change from baseline was calculated as the average of the Week 1-Week 52 values minus the baseline value.</description>
        <time_frame>Baseline and Week 1 through Week 52</time_frame>
        <population>Participants in the ITT Population for which at least 1 week of diary data were provided</population>
        <group_list>
          <group group_id="O1">
            <title>FSC DISKUS 250/50 mcg BID for 52 Weeks</title>
            <description>Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 micrograms (mcg) twice daily (BID) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>FP DISKUS 250 mcg BID for 52 Weeks</title>
            <description>Fluticasone Propionate (FP) DISKUS 250 mcg BID for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Percentage of Symptom-free Days Over Weeks 1-52</title>
          <description>A symptom-free day was defined as a day without asthma symptoms, as measured via the daily asthma symptom score (measuring symptoms during the day and previous night) on a 6-point scale (ranging from 0 to 5). A symptom score of 0=no symptoms, 1=symptoms for one short period, 2=symptoms for two or more short periods, 3=symptoms that did not affect normal daily activities, 4=symptoms that did affect normal daily activities, 5=symptoms so severe that daily activities could not be performed. Change from baseline was calculated as the average of the Week 1-Week 52 values minus the baseline value.</description>
          <population>Participants in the ITT Population for which at least 1 week of diary data were provided</population>
          <units>Percentage of symptom-free days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.1" spread="2.02"/>
                    <measurement group_id="O2" value="28.5" spread="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Asthma Attacks Per Participant Per Year</title>
        <description>The rate of asthma attacks was defined as the mean number of attacks per participant per year. An asthma attack was defined as a 20% decrease in AM PEF, a 70% increase in albuterol use, or the occurrence of an asthma exacerbation requiring oral steroids or hospitalization.</description>
        <time_frame>Week 1 through Week 52</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>FSC DISKUS 250/50 mcg BID for 52 Weeks</title>
            <description>Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 micrograms (mcg) twice daily (BID) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>FP DISKUS 250 mcg BID for 52 Weeks</title>
            <description>Fluticasone Propionate (FP) DISKUS 250 mcg BID for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Asthma Attacks Per Participant Per Year</title>
          <description>The rate of asthma attacks was defined as the mean number of attacks per participant per year. An asthma attack was defined as a 20% decrease in AM PEF, a 70% increase in albuterol use, or the occurrence of an asthma exacerbation requiring oral steroids or hospitalization.</description>
          <population>ITT Population</population>
          <units>attacks per participant per year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="306"/>
                <count group_id="O2" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" lower_limit="1.36" upper_limit="2.59"/>
                    <measurement group_id="O2" value="2.14" lower_limit="1.55" upper_limit="2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>FSC DISKUS 250/50 mcg BID for 52 Weeks</title>
          <description>Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 micrograms (mcg) twice daily (BID) for 52 weeks</description>
        </group>
        <group group_id="E2">
          <title>FP DISKUS 250 mcg BID for 52 Weeks</title>
          <description>Fluticasone Propionate (FP) DISKUS 250 mcg BID for 52 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Iron deficiency anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Myocardial ischemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Amoebic dysentery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Localized infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Premature baby</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma (exacerbation)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="183" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="203" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="96" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>Allergic Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

